Changchun High-Tech (000661.SZ): Clinical trial application for the combination formulation of recombinant human anti-respiratory syncytial virus monoclonal antibody injection accepted

Zhitong Finance APP News: Changchun High-Tech (000661.SZ) has announced that its subsidiary, Changchun Bcht Biotechnology Co., Ltd. (referred to as "Bcht"), recently received the "Notice of Acceptance" from the National Medical Products Administration for the clinical trial application of the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation (referred to as "RSV antibody").